{
  "docId": "019de075-e430-7299-a96e-811e562ad763",
  "docSlug": "dd1cc6bfd53a92cef2d40347c5bc25e6",
  "documentTitle": "Alkermes | Results Presentation Deck | 27 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 27,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; AE: Adverse Event; SAE: Serious Adverse Event.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e430-7299-a96e-811e562ad763/16",
  "deckHref": "/decks/019de075-e430-7299-a96e-811e562ad763",
  "deckJsonHref": "/decks/019de075-e430-7299-a96e-811e562ad763.json",
  "deckAnchorHref": "/decks/019de075-e430-7299-a96e-811e562ad763#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.12,
        "x": 0.85,
        "y": 0.02
      },
      "kind": "callout",
      "text": "Healthy Volunteers",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a370ce9-6518-4130-8e5c-067cbd1e058b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "list",
      "text": "Maximum tolerated dose not reached. Most AEs were mild and observed at doses ≥15 mg (SAD) and ≥8 mg (MAD). No severe AEs or SAEs reported. Most AEs were transient. No safety signal in vitals/labs/ECGs. One participant discontinued in MAD.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0b90c3a-2003-40f9-a0fd-06b1370317f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "AE: adverse event; ECG: electrocardiogram; MAD: multiple ascending dose; SAD: single ascending dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a189e7c-f746-4999-a0e0-56620916d826",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "ALKS 2680 Was Generally Well Tolerated in Healthy Volunteers in Both SAD and MAD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81cb8c2c-5aa7-47d8-a76d-e8a05e5d3059",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 13,
      "beatId": "a2d3f125-9d63-41e7-ad4b-d97f1d4906af",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The preliminary results from a Phase 1 study of ALKS 2680 demonstrate potential for growth",
      "position": 2,
      "confidence": 0.7,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}